Advertisement

Prominent Precision Medicine Clinical Trials in Oncology Around the World

  • George Louis Kumar
Chapter

Abstract

Precision medicine (PM) is a tailored treatment aimed to give the right drug to the right patient at the right dosage and at the right time. In PM, physicians and other stakeholders consider differences in genes, microbiome composition, health history, lifestyle diet, socioeconomic status, and lifestyles when devising treatment regimens for patients. The success of PM depends on (1) having accurate diagnostic tests that identify patients who can benefit from targeted therapies, (2) an enhanced understanding of the molecular pathology of disease gained from genomic studies, and (3) patient-centric clinical trials for therapeutic development. This chapter gives a broad overview of some prominent, “past and present,” precision medicine clinical trials conducted around the world using the “-omics” technologies, immunohistochemistry, predictive biomarkers, cytogenetics, fluorescence in situ hybridization, and immuno- and gene therapy.

Keywords

Precision medicine clinical trials White House Immunotherapy IMPaCT Exceptional responders study Tisagenlecleucel Cancer Moonshot program CAR-T therapy TAPUR 

References

  1. 1.
    The Precision Medicine Initiative. https://obamawhitehouse.archives.gov/precision-medicine. Last Accessed November 22, 2017.
  2. 2.
    Jameson JL, Longo DL. Precision medicine – personalized, problematic, and promising. N Engl J Med. 2015;372:2229–34.CrossRefGoogle Scholar
  3. 3.
    Olson MV. Historical note: a behind-the-scenes story of precision medicine. Genomics Proteomics Bioinformatics. 2017;15:3–10. National Research Council. 2011.CrossRefGoogle Scholar
  4. 4.
    Toward precision medicine: building a knowledge network for biomedical research and a new taxonomy of disease. Washington, DC: The National Academies Press.  https://doi.org/10.17226/13284.
  5. 5.
    Ashley EA. Towards precision medicine. Nat Rev Genet. 2016;17(9):507–22.CrossRefGoogle Scholar
  6. 6.
    Vargas AJ, Harris CC. Biomarker development in the precision medicine era: lung cancer as a case study. Nat Rev Cancer. 2016;16(8):525–37.CrossRefGoogle Scholar
  7. 7.
    American Association of Cancer Research (AACR) Cancer Progress Report. 2017.Google Scholar
  8. 8.
    Ying T, Wen Y, Dimitrov D. Precision immunomedicine. Emerging Microbes Infect. 2017;6:e25.CrossRefGoogle Scholar
  9. 9.
    Kroschinsky F, Stölzel F, von Bonin S, et al. New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management. Crit Care. 2017;21:89.CrossRefGoogle Scholar
  10. 10.
    Rosenbaum L. Tragedy, perseverance, and chance—the story of CAR-T therapy. N Engl J Med. 2017;377:1313–5.CrossRefGoogle Scholar
  11. 11.
    Schacter B. The new medicine$. How drugs are created, approved, marketed, and sold. Westport: Praeger Publishers; 2006.Google Scholar
  12. 12.
    Hays P. Advancing healthcare through personalized medicine. Boco Raton: CRC Press; 2017.CrossRefGoogle Scholar
  13. 13.
    Roper N, et al. The landscape of precision cancer medicine clinical trials in the United States. Cancer Treat Rev. 2015;41(5):385–90.CrossRefGoogle Scholar
  14. 14.
    The Changing Face of Clinical Trials. NEJM. Retrieved from: http://www.nejm.org/page/clinical-trials-series. Last Accessed 22 Nov 2017.

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Targos Inc.IssaquahUSA

Personalised recommendations